These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25941218)

  • 21. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus.
    He F; Kumar SR; Syed Khader SM; Tan Y; Prabakaran M; Kwang J
    Antiviral Res; 2013 Oct; 100(1):207-14. PubMed ID: 23954322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-influenza virus effects of cocoa.
    Kamei M; Nishimura H; Takahashi T; Takahashi N; Inokuchi K; Mato T; Takahashi K
    J Sci Food Agric; 2016 Mar; 96(4):1150-8. PubMed ID: 25847473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.
    Retamal M; Abed Y; Rhéaume C; Cappelletti F; Clementi N; Mancini N; Clementi M; Burioni R; Boivin G
    Antimicrob Agents Chemother; 2015 May; 59(5):2647-53. PubMed ID: 25691648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
    Boltz DA; Ilyushina NA; Arnold CS; Babu YS; Webster RG; Govorkova EA
    Antiviral Res; 2008 Nov; 80(2):150-7. PubMed ID: 18573280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newly established monoclonal antibodies for immunological detection of H5N1 influenza virus.
    Ohnishi K; Takahashi Y; Kono N; Nakajima N; Mizukoshi F; Misawa S; Yamamoto T; Mitsuki YY; Fu S; Hirayama N; Ohshima M; Ato M; Kageyama T; Odagiri T; Tashiro M; Kobayashi K; Itamura S; Tsunetsugu-Yokota Y
    Jpn J Infect Dis; 2012; 65(1):19-27. PubMed ID: 22274153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human monoclonal antibodies derived from a patient infected with 2009 pandemic influenza A virus broadly cross-neutralize group 1 influenza viruses.
    Pan Y; Sasaki T; Kubota-Koketsu R; Inoue Y; Yasugi M; Yamashita A; Ramadhany R; Arai Y; Du A; Boonsathorn N; Ibrahim MS; Daidoji T; Nakaya T; Ono K; Okuno Y; Ikuta K; Watanabe Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):42-8. PubMed ID: 24858683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment.
    Robinson KM; Ramanan K; Tobin JM; Nickolich KL; Pilewski MJ; Kallewaard NL; Sellman BR; Cohen TS; Alcorn JF
    JCI Insight; 2019 Jul; 4(14):. PubMed ID: 31341107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
    Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
    Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
    Kubo S; Kakuta M; Yamashita M
    Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation and Characterization of Monoclonal Antibodies Specific to Avian Influenza H5N1 Hemagglutinin Protein.
    Malik A; Mallajosyula VV; Mishra NN; Varadarajan R; Gupta SK
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):436-41. PubMed ID: 26683184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1.
    Chen Y; Luo W; Wu WL; Fang Z; Xia L; Gui X; Chen Y; Chen H; Shih JW; Xia N
    Antiviral Res; 2010 Jul; 87(1):81-4. PubMed ID: 20450935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs.
    Smee DF; von Itzstein M; Bhatt B; Tarbet EB
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6328-33. PubMed ID: 23027194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].
    Klimova RR; Masalova OV; Burtseva EI; Chichev EV; Lesnova EI; Oskerko TA; Mukasheva EA; Rudneva IA; Lvov DK; Kushch AA
    Vopr Virusol; 2011; 56(3):15-20. PubMed ID: 21786621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tackling influenza with broadly neutralizing antibodies.
    Corti D; Cameroni E; Guarino B; Kallewaard NL; Zhu Q; Lanzavecchia A
    Curr Opin Virol; 2017 Jun; 24():60-69. PubMed ID: 28527859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades.
    Mak TM; Hanson BJ; Tan YJ
    Antiviral Res; 2014 Jul; 107():76-83. PubMed ID: 24797696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
    Sidwell RW; Barnard DL; Day CW; Smee DF; Bailey KW; Wong MH; Morrey JD; Furuta Y
    Antimicrob Agents Chemother; 2007 Mar; 51(3):845-51. PubMed ID: 17194832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation, characterization, and protective ability of mouse monoclonal antibodies against the HA of A (H1N1) influenza virus.
    Wang L; Yang F; Xiao Y; Chen B; Liu F; Cheng L; Yao H; Wu N; Wu H
    J Med Virol; 2022 Jun; 94(6):2558-2567. PubMed ID: 35005794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.